BI 1819479
Sponsors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim
Conditions
HealthyIdiopathic Pulmonary Fibrosisidiopathic pulmonary fibrosis
Phase 1
A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food
CompletedNCT04801693
Start: 2021-05-26End: 2022-04-25Updated: 2022-05-04
A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479
CompletedNCT05440799
Start: 2022-07-20End: 2023-08-02Updated: 2023-08-14
A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood
CompletedNCT05467475
Start: 2022-10-18End: 2023-01-23Updated: 2023-01-26
A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated
CompletedNCT05469646
Start: 2022-08-03End: 2022-12-27Updated: 2023-04-05
A Study to Test How BI 1819479 is Taken up and Processed by the Body
TerminatedNCT07065617
Start: 2025-08-04End: 2025-11-04Updated: 2026-03-17
Phase 2
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
CompletedNCT06335303
Start: 2024-09-05End: 2026-01-16Updated: 2026-02-18
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety and tolerability of different doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF).
CompletedCTIS2023-508395-11-00
Start: 2024-09-10End: 2026-01-09Target: 123Updated: 2025-12-22